肿瘤细胞治疗研究
FRONTIER PAPERS
Spatial dissection of antibody-drug conjugate/radiopharmaceutical therapy targets defines heterogeneous expression landscapes and therapeutic implicat
这些发现确定了 RT 中一组具有生物学和临床相关性的表面靶点，并为儿童癌症中合理的 ADC 和 RPT 靶点开发提供了转化蓝图。
FECH, a novel metabolic target influencing CAR T-cell phenotype and function.
Are the current preclinical models adequate to evaluate CAR-T cell therapy in pediatric high-grade gliomas?
Optimized L1CAM-CAR T cells enhance activity against moderate-antigen-density rhabdomyosarcoma models.
Anti-CD7 fratricide-resistant chimeric antigen receptor T cells for relapsed/refractory acute myeloid leukemia.
Homeodomain-driven oncogenic diversion to a γδTCR phenotype in T-cell acute lymphoblastic leukemia.
Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort.
CAR-T22.19 疗法在高危儿科人群中显示出良好的安全性特征和有前景的临床活性，其双靶向设计使 CD19 阴性白血病获得疾病控制。
CART-Cell Therapy in Pediatric Acute Lymphoblastic Leukemia: A Review for General Pediatricians.
First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Re
IL15-CIK 单药治疗可行且安全，在造血干细胞移植后显示出有前景的预防复发活性。临床结局受治疗开始时疾病负荷和既往血清治疗强烈影响，支持在未来移植后免疫治疗策略中优化患者选择和治疗时机。
Intrinsic immune properties of carrier MSC impact on the clinical outcome of children with solid tumors receiving oncolytic virotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
